Immunomedics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:1982
Lead Investor(s):Goldman, Sachs & Co.
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Immunomedics's estimated revenue is currently $34.6M per year.
  • Immunomedics received $125.0M in venture funding in May 2017.
  • Immunomedics's estimated revenue per employee is $96821

Employee Data

  • Immunomedics has 357 Employees.
  • Immunomedics grew their employee count by 27% last year.
  • Immunomedics currently has 22 job openings.

Executive Contacts

NameTitle
Joseph AmalrajTechnical Director, IT at Immunomedics Inc
Rahul PatelDirector, Validation & Compliance
Brendan DelaneyChief Commercial Officer
Eugene ParkSenior Director, Head of Marketing
Joseph HenleyDirector, Bioreactor Production
Karen HummelDirector, National Accounts
Charles BaumMember Board Of Directors
Shalin ShahSenior Director, Pricing, Contracting, & Market Access
Ruchi MallyaAssociate Director, Forecasting & Analytics
Paul QuinnNorth Central Region Business Director

What Is Immunomedics?

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.

keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power

357

Number of Employees

$34.6M

Revenue (est)

22

Current Jobs

27%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
GENEWIZ
$75.8M5283%
Hitachi Chemica...
$29.9M24213%
Canfield Scient...
$29.3M202-32%
Thomas Scientif...
$21.5M18123%
L Oreal USA
N/A0N/A
Insmed Incorpor...
$97.3M42111%
Amicus Therapeu...
$91.2M55417%$294.6M
Celularity
N/A14916%$367.7M
Legend Biotech ...
$12.8M98227%
ADMA Biologics
$23.1M16610%

Immunomedics News

12-Sep-19 - Immunomedics to Host Investor Event and Webcast on ...

12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical ...

12-Sep-19 - Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in ...

Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid ...

4-Sep-19 - Immunomedics Announces Oral Presentation of Sacituzumab ...

Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress ...

Immunomedics Funding

DateAmountRoundLead InvestorsReference
2004-01-15$10.0MnotesArticle
2005-04-28$36.7MUndisclosedMultipleArticle
2014-05-05$30.2MUndisclosedArticle
2015-02-09$96.4MUndisclosedGoldman, Sachs & Co.Article
2017-05-08$125.0MUndisclosedArticle

Immunomedics Executive Hires

DateNameTitleReference
2001-09-12Gerald GormanCFOArticle
2002-03-26Terence RuggCMO & SVPArticle
2002-05-03Ivan HorakEVP Research & DevelopmentArticle
2013-09-04Peter PfreundschuhCFO/VP FinanceArticle
2015-01-07Francois E. WilhelmChief Medical OfficerArticle
2016-06-22Michael R. GaroneVP Finance/CFOArticle
2017-05-08Michael GaroneInterim CEOArticle
2019-02-27Scott Canuteexecutive directorArticle